Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity.
This trial was conducted to study the frequency of the slow acetylator phenotype in asymptomatic HIV patients having no previous reaction to sulfa-drugs, and to compare this frequency with the frequency found in healthy controls. Results show that HIV alone is not capable of modifying the acetylator phenotype; the prevalence of slow acetylator phenotype is the same in immune competent subjects and HIV-positive patients. It is more common in HIV-positive patients with a CD4+ lymphocyte count of less than 200 mm-3.
Quirino
T
T
Bonfanti
P
P
Arcidiacono
M
M
Pusterla
L
L
Cagni
A
A
Scaglione
F
F
Milazzo
F
F
D000107:Acetylation; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000235:genetics* / Q000378:metabolism; D006679:HIV Seropositivity; D006801:Humans; D007700:Kinetics; D008297:Male; D010641:Phenotype; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination